Skip to main content
Top
Published in: Breast Cancer Research 5/2011

01-10-2011 | Review

Male breast carcinoma: increased awareness needed

Authors: Jonathan White, Olive Kearins, David Dodwell, Kieran Horgan, Andrew M Hanby, Valerie Speirs

Published in: Breast Cancer Research | Issue 5/2011

Login to get access

Abstract

Male breast carcinoma is a rare condition. Few male breast cancer-specific epidemiological or clinical trial data are available - our understanding of male breast cancer thus comes from studies of female breast cancer, painting an inaccurate picture when it comes to determining contributing factors. Clinicians report an increase in diagnoses of male breast cancer but this has not been formally reported. We therefore undertook a review of data obtained from four western nations: England, Scotland, Canada and Australia. When adjusted for age, this review clearly showed an increase in the incidence of male breast cancer over a 15-year period. Reasons for the increased incidence are discussed in the context of suggested risk factors such as BRCA2 and lifestyle changes over the past few decades. The clinical management of male breast carcinoma is considered, in particular the potential role of aromatase inhibitors and fulvestrant and targeting pathways involving prolactin and androgen receptor.
Appendix
Available only for authorised users
Literature
2.
go back to reference Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, Eds: Cancer Incidence in Five Continents. 2002, IARC Scientific Publication No. 155. Lyon: IACR Press, VIII: Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, Eds: Cancer Incidence in Five Continents. 2002, IARC Scientific Publication No. 155. Lyon: IACR Press, VIII:
3.
go back to reference Thompson D, Easton D, Breast Cancer Linkage Consortium: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001, 68: 410-419. 10.1086/318181.CrossRefPubMedPubMedCentral Thompson D, Easton D, Breast Cancer Linkage Consortium: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001, 68: 410-419. 10.1086/318181.CrossRefPubMedPubMedCentral
4.
go back to reference Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhasen S, Jonasson JG, Tavtigian SV, Tulnius H, Ogmunsdottir HM, Eyfjord JE: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996, 13: 117-119. 10.1038/ng0596-117.CrossRefPubMed Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhasen S, Jonasson JG, Tavtigian SV, Tulnius H, Ogmunsdottir HM, Eyfjord JE: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996, 13: 117-119. 10.1038/ng0596-117.CrossRefPubMed
5.
go back to reference Thorlacius S, Tryggvadottir L, Olafsdottir GH, Jonasson JG, Ogmunsdottir HM, Tulnius H, Eyfjord JE: Linkage to BRCA2 region in hereditary male breast cancer. Lancet. 1995, 346: 544-545. 10.1016/S0140-6736(95)91383-1.CrossRefPubMed Thorlacius S, Tryggvadottir L, Olafsdottir GH, Jonasson JG, Ogmunsdottir HM, Tulnius H, Eyfjord JE: Linkage to BRCA2 region in hereditary male breast cancer. Lancet. 1995, 346: 544-545. 10.1016/S0140-6736(95)91383-1.CrossRefPubMed
6.
go back to reference Weiss JR, Moysich KB, Swede H: Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14: 20-26.CrossRefPubMed Weiss JR, Moysich KB, Swede H: Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14: 20-26.CrossRefPubMed
7.
go back to reference Brinton LA, Richesson DA, Gierach GL, Lacey JV, Park Y, Hollenback AR, Schatzkin A: Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst. 2008, 100: 1477-1481. 10.1093/jnci/djn329.CrossRefPubMedPubMedCentral Brinton LA, Richesson DA, Gierach GL, Lacey JV, Park Y, Hollenback AR, Schatzkin A: Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst. 2008, 100: 1477-1481. 10.1093/jnci/djn329.CrossRefPubMedPubMedCentral
8.
go back to reference Alali L, Honarpisheh H, Shaaban A, Speirs V: Conditions of the male breast: gynaecomastia and male breast cancer (Review). Mol Med Report. 2010, 3: 21-26. Alali L, Honarpisheh H, Shaaban A, Speirs V: Conditions of the male breast: gynaecomastia and male breast cancer (Review). Mol Med Report. 2010, 3: 21-26.
9.
go back to reference Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN: Breast carcinoma in men: a population-based study. Cancer. 2004, 101: 51-57. 10.1002/cncr.20312.CrossRefPubMed Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN: Breast carcinoma in men: a population-based study. Cancer. 2004, 101: 51-57. 10.1002/cncr.20312.CrossRefPubMed
10.
go back to reference Hodgson NC, Button JH, Franceschi D, Moffat FL, Livingstone AS: Male breast cancer: is the incidence increasing?. Ann Surg Oncol. 2004, 11: 751-755. 10.1245/ASO.2004.01.001.CrossRefPubMed Hodgson NC, Button JH, Franceschi D, Moffat FL, Livingstone AS: Male breast cancer: is the incidence increasing?. Ann Surg Oncol. 2004, 11: 751-755. 10.1245/ASO.2004.01.001.CrossRefPubMed
11.
go back to reference Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H: Male breast cancer: is the scenario changing. World J Surg Oncol. 2008, 6: 58-69. 10.1186/1477-7819-6-58.CrossRefPubMedPubMedCentral Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H: Male breast cancer: is the scenario changing. World J Surg Oncol. 2008, 6: 58-69. 10.1186/1477-7819-6-58.CrossRefPubMedPubMedCentral
12.
go back to reference Speirs V, Shaaban AM: The rising incidence of male breast cancer. Breast Cancer Res Treat. 2009, 115: 429-430. 10.1007/s10549-008-0053-y.CrossRefPubMed Speirs V, Shaaban AM: The rising incidence of male breast cancer. Breast Cancer Res Treat. 2009, 115: 429-430. 10.1007/s10549-008-0053-y.CrossRefPubMed
17.
go back to reference Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004, 4: 579-591. 10.1038/nrc1408.CrossRefPubMed Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004, 4: 579-591. 10.1038/nrc1408.CrossRefPubMed
18.
go back to reference Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, Berrino F, Tjønneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F, Nagel G, Boeing H, Trichopoulos D, Economou G, Bellos G, Palli D, Tumino R, Panico S, Sacerdote C, Krogh V, Peeters PH, Bueno-de-Mesquita HB, Lund E, Ardanaz E, Amiano P, Pera G, Quirós JR, Martínez C, et al: Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2004, 111: 762-771. 10.1002/ijc.20315.CrossRefPubMed Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, Berrino F, Tjønneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F, Nagel G, Boeing H, Trichopoulos D, Economou G, Bellos G, Palli D, Tumino R, Panico S, Sacerdote C, Krogh V, Peeters PH, Bueno-de-Mesquita HB, Lund E, Ardanaz E, Amiano P, Pera G, Quirós JR, Martínez C, et al: Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2004, 111: 762-771. 10.1002/ijc.20315.CrossRefPubMed
19.
go back to reference Khan N, Afaq F, Mukhtar H: Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett. 2010, 293: 133-143. 10.1016/j.canlet.2009.12.013.CrossRefPubMedPubMedCentral Khan N, Afaq F, Mukhtar H: Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett. 2010, 293: 133-143. 10.1016/j.canlet.2009.12.013.CrossRefPubMedPubMedCentral
20.
go back to reference Darbre PD, Charles AK: Environmental oestrogens and breast cancer: evidence for combined involvement of dietary, household and cosmetic xenooestrogens. Anticancer Res. 2010, 30: 815-827.PubMed Darbre PD, Charles AK: Environmental oestrogens and breast cancer: evidence for combined involvement of dietary, household and cosmetic xenooestrogens. Anticancer Res. 2010, 30: 815-827.PubMed
21.
go back to reference Agrawal A, Ayantunde AA, Rampaul A, Robertson JFR: Male breast cancer: a review of clinical management. Breast Cancer Res Treat. 2007, 103: 11-21. 10.1007/s10549-006-9356-z.CrossRefPubMed Agrawal A, Ayantunde AA, Rampaul A, Robertson JFR: Male breast cancer: a review of clinical management. Breast Cancer Res Treat. 2007, 103: 11-21. 10.1007/s10549-006-9356-z.CrossRefPubMed
22.
go back to reference De Cicco C, Baio SM, Veronesi P, Trifirò G, Ciprian A, Vento A, Rososchansky J, Viale G, Paganelli G: Sentinel node biopsy in male breast cancer. Nucl Med Commun. 2004, 25: 139-143. 10.1097/00006231-200402000-00008.CrossRefPubMed De Cicco C, Baio SM, Veronesi P, Trifirò G, Ciprian A, Vento A, Rososchansky J, Viale G, Paganelli G: Sentinel node biopsy in male breast cancer. Nucl Med Commun. 2004, 25: 139-143. 10.1097/00006231-200402000-00008.CrossRefPubMed
23.
go back to reference Bagley CS, Wesley MN, Young RC. Lippman ME: Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol. 1987, 10: 55-60. 10.1097/00000421-198702000-00013.CrossRefPubMed Bagley CS, Wesley MN, Young RC. Lippman ME: Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol. 1987, 10: 55-60. 10.1097/00000421-198702000-00013.CrossRefPubMed
24.
go back to reference Patel HZ 2nd, Buzdar AU, Hortobagyi GN: Role of adjuvant chemotherapy in male breast cancer. Cancer. 1989, 64: 1583-1585. 10.1002/1097-0142(19891015)64:8<1583::AID-CNCR2820640804>3.0.CO;2-Q.CrossRefPubMed Patel HZ 2nd, Buzdar AU, Hortobagyi GN: Role of adjuvant chemotherapy in male breast cancer. Cancer. 1989, 64: 1583-1585. 10.1002/1097-0142(19891015)64:8<1583::AID-CNCR2820640804>3.0.CO;2-Q.CrossRefPubMed
25.
go back to reference Farrow JH, Adair FE: Effect of orchidectomy on skeletal metastases from cancer of the male breast. Science. 1942, 95: 654-10.1126/science.95.2478.654.CrossRefPubMed Farrow JH, Adair FE: Effect of orchidectomy on skeletal metastases from cancer of the male breast. Science. 1942, 95: 654-10.1126/science.95.2478.654.CrossRefPubMed
26.
go back to reference Treves N: The treatment of cancer, especially inoperable cancer, of the male breast by ablative surgery (orchiectomy, adrenalectomy, and hypophysectomy) and hormone therapy (oestrogens and corticosteroids); an analysis of 42 patients. Cancer. 1959, 12: 820-882. 10.1002/1097-0142(195907/08)12:4<820::AID-CNCR2820120427>3.0.CO;2-9.CrossRefPubMed Treves N: The treatment of cancer, especially inoperable cancer, of the male breast by ablative surgery (orchiectomy, adrenalectomy, and hypophysectomy) and hormone therapy (oestrogens and corticosteroids); an analysis of 42 patients. Cancer. 1959, 12: 820-882. 10.1002/1097-0142(195907/08)12:4<820::AID-CNCR2820120427>3.0.CO;2-9.CrossRefPubMed
27.
go back to reference Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA: Carcinoma of the male breast. Ann Intern Med. 1992, 117: 771-777.CrossRefPubMed Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA: Carcinoma of the male breast. Ann Intern Med. 1992, 117: 771-777.CrossRefPubMed
28.
29.
go back to reference Murphy CE, Carder PJ, Lansdown MR, Speirs V: Steroid hormone receptor expression in male breast cancer. Eur J Surg Oncol. 2006, 32: 44-47. 10.1016/j.ejso.2005.09.013.CrossRefPubMed Murphy CE, Carder PJ, Lansdown MR, Speirs V: Steroid hormone receptor expression in male breast cancer. Eur J Surg Oncol. 2006, 32: 44-47. 10.1016/j.ejso.2005.09.013.CrossRefPubMed
30.
go back to reference Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Lea JC, Richards D, Ellis SH: Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet. 1983, 2: 450-CrossRefPubMed Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Lea JC, Richards D, Ellis SH: Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet. 1983, 2: 450-CrossRefPubMed
31.
go back to reference Ribeiro GG: Tamoxifen in the treatment of male breast carcinoma. Clin Radiol. 1983, 34: 625-628. 10.1016/S0009-9260(83)80408-5.CrossRefPubMed Ribeiro GG: Tamoxifen in the treatment of male breast carcinoma. Clin Radiol. 1983, 34: 625-628. 10.1016/S0009-9260(83)80408-5.CrossRefPubMed
32.
go back to reference Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G: Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983, 143: 237-240. 10.1001/archinte.143.2.237.CrossRefPubMed Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G: Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983, 143: 237-240. 10.1001/archinte.143.2.237.CrossRefPubMed
33.
go back to reference Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, Hortobagyi GN: Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005, 104: 2359-2364. 10.1002/cncr.21526.CrossRefPubMed Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, Hortobagyi GN: Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005, 104: 2359-2364. 10.1002/cncr.21526.CrossRefPubMed
34.
go back to reference Vinod SK, Pendlebury SC: Carcinoma of the male breast: a review of adjuvant therapy. Australas Radiol. 1999, 43: 69-72. 10.1046/j.1440-1673.1999.00601.x.CrossRefPubMed Vinod SK, Pendlebury SC: Carcinoma of the male breast: a review of adjuvant therapy. Australas Radiol. 1999, 43: 69-72. 10.1046/j.1440-1673.1999.00601.x.CrossRefPubMed
36.
go back to reference Pasqualini JR, Chetrite G, Nguyen B-L, Maloche C, Delalonde L, Talbi M, Feinstein MC, Blacker C, Botella J, Paris J: Estrone sulfate-sulfatase and 17β-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J Steroid Biochem Mol Biol. 1995, 53: 407-412. 10.1016/0960-0760(95)00116-H.CrossRefPubMed Pasqualini JR, Chetrite G, Nguyen B-L, Maloche C, Delalonde L, Talbi M, Feinstein MC, Blacker C, Botella J, Paris J: Estrone sulfate-sulfatase and 17β-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J Steroid Biochem Mol Biol. 1995, 53: 407-412. 10.1016/0960-0760(95)00116-H.CrossRefPubMed
37.
go back to reference Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ: American Society of Clinical OncologyAmerican Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010, 28: 3784-3796. 10.1200/JCO.2009.26.3756.CrossRefPubMed Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ: American Society of Clinical OncologyAmerican Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010, 28: 3784-3796. 10.1200/JCO.2009.26.3756.CrossRefPubMed
38.
go back to reference Sasano H, Kimura M, Shizawa S, Kimura N, Nagura H: Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J Clin Endocrinol Metab. 1996, 81: 3063-3067. 10.1210/jc.81.8.3063.PubMed Sasano H, Kimura M, Shizawa S, Kimura N, Nagura H: Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J Clin Endocrinol Metab. 1996, 81: 3063-3067. 10.1210/jc.81.8.3063.PubMed
39.
go back to reference Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D: Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat. 2007, 105: 169-175. 10.1007/s10549-006-9448-9.CrossRefPubMed Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D: Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat. 2007, 105: 169-175. 10.1007/s10549-006-9448-9.CrossRefPubMed
40.
go back to reference Giordano SH, Valero V, Buzdar AU, Hortobagyi GN: Efficacy of anastrozole in male breast cancer. Am J Clin Oncol. 2002, 25: 235-237. 10.1097/00000421-200206000-00006.CrossRefPubMed Giordano SH, Valero V, Buzdar AU, Hortobagyi GN: Efficacy of anastrozole in male breast cancer. Am J Clin Oncol. 2002, 25: 235-237. 10.1097/00000421-200206000-00006.CrossRefPubMed
41.
go back to reference Italiano A, Largillier R, Marcy PY, Foa C, Ferrero JM, Hartmann MT, Namer M: Complete remission obtained with letrozole in a man with metastatic breast cancer. Rev Med Interne. 2004, 225: 323-324.CrossRef Italiano A, Largillier R, Marcy PY, Foa C, Ferrero JM, Hartmann MT, Namer M: Complete remission obtained with letrozole in a man with metastatic breast cancer. Rev Med Interne. 2004, 225: 323-324.CrossRef
42.
go back to reference Zabolotny BP, Zalai CV, Meterissian SH: Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol. 2005, 90: 26-30. 10.1002/jso.20233.CrossRefPubMed Zabolotny BP, Zalai CV, Meterissian SH: Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol. 2005, 90: 26-30. 10.1002/jso.20233.CrossRefPubMed
43.
go back to reference Arriola E, Hui E, Dowsett M, Smith IE: Aromatase inhibitors and male breast cancer. Clin Transl Oncol. 2007, 9: 192-194. 10.1007/s12094-007-0034-3.CrossRefPubMed Arriola E, Hui E, Dowsett M, Smith IE: Aromatase inhibitors and male breast cancer. Clin Transl Oncol. 2007, 9: 192-194. 10.1007/s12094-007-0034-3.CrossRefPubMed
44.
go back to reference Visram H, Kanji F, Dent SF: Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol. 2010, 17: 17-21.PubMedPubMedCentral Visram H, Kanji F, Dent SF: Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol. 2010, 17: 17-21.PubMedPubMedCentral
45.
go back to reference Turner KJ, Morley M, Atanassova N, Swanston ID, Sharpe RM: Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol. 2000, 164: 225-238. 10.1677/joe.0.1640225.CrossRefPubMed Turner KJ, Morley M, Atanassova N, Swanston ID, Sharpe RM: Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol. 2000, 164: 225-238. 10.1677/joe.0.1640225.CrossRefPubMed
46.
go back to reference Mauras N, O'Brien KO, Klein KO, Hayes V: Oestrogen suppression in males: metabolic effects. J Clin Endocrinol Metab. 2000, 85: 2370-2377. 10.1210/jc.85.7.2370.PubMed Mauras N, O'Brien KO, Klein KO, Hayes V: Oestrogen suppression in males: metabolic effects. J Clin Endocrinol Metab. 2000, 85: 2370-2377. 10.1210/jc.85.7.2370.PubMed
47.
go back to reference Trunet PF, Mueller P, Bhatnagar AS, Dickes I, Monnet G, White G: Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab. 1993, 77: 319-323. 10.1210/jc.77.2.319.PubMed Trunet PF, Mueller P, Bhatnagar AS, Dickes I, Monnet G, White G: Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab. 1993, 77: 319-323. 10.1210/jc.77.2.319.PubMed
48.
go back to reference Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A: Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol. 2010, 21: 1243-1245. 10.1093/annonc/mdp450.CrossRefPubMed Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A: Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol. 2010, 21: 1243-1245. 10.1093/annonc/mdp450.CrossRefPubMed
49.
go back to reference Giordano SH, Hortobagyi GN: Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol. 2006, 24: e42-e43. 10.1200/JCO.2006.07.2397.CrossRefPubMed Giordano SH, Hortobagyi GN: Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol. 2006, 24: e42-e43. 10.1200/JCO.2006.07.2397.CrossRefPubMed
51.
go back to reference Agrawal A, Cheung KL, Robertson JF: Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat. 2007, 101: 123-10.1007/s10549-006-9266-0.CrossRefPubMed Agrawal A, Cheung KL, Robertson JF: Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat. 2007, 101: 123-10.1007/s10549-006-9266-0.CrossRefPubMed
52.
go back to reference de la Haba Rodriguez JR, Porras Quintela I, Pulido Cortijo G, Berciano Guerrero M, Aranda E: Fulvestrant in advanced male breast cancer. Ann Oncol. 2009, 20: 1896-1897. 10.1093/annonc/mdp413.CrossRefPubMed de la Haba Rodriguez JR, Porras Quintela I, Pulido Cortijo G, Berciano Guerrero M, Aranda E: Fulvestrant in advanced male breast cancer. Ann Oncol. 2009, 20: 1896-1897. 10.1093/annonc/mdp413.CrossRefPubMed
53.
go back to reference Masci G, Gandini C, Zuradelli M, Pedrazzoli P, Torrisi R, Lutman FR, Santoro A: Fulvestrant for advanced male breast cancer patients: a case series. Ann Oncol. 2011, 22: 985-993. 10.1093/annonc/mdr005.CrossRefPubMed Masci G, Gandini C, Zuradelli M, Pedrazzoli P, Torrisi R, Lutman FR, Santoro A: Fulvestrant for advanced male breast cancer patients: a case series. Ann Oncol. 2011, 22: 985-993. 10.1093/annonc/mdr005.CrossRefPubMed
54.
go back to reference Agarwal PK, Tandon S, Agrawal AK, Kumar S: Highly specific sites of prolactin binding in benign and malignant breast tissue. Indian J Exp Biol. 1989, 27: 1035-1038.PubMed Agarwal PK, Tandon S, Agrawal AK, Kumar S: Highly specific sites of prolactin binding in benign and malignant breast tissue. Indian J Exp Biol. 1989, 27: 1035-1038.PubMed
55.
go back to reference Gill S, Peston D, Vonderhaar BK, Shousha S: Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol. 2001, 54: 956-960. 10.1136/jcp.54.12.956.CrossRefPubMedPubMedCentral Gill S, Peston D, Vonderhaar BK, Shousha S: Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol. 2001, 54: 956-960. 10.1136/jcp.54.12.956.CrossRefPubMedPubMedCentral
56.
go back to reference Ferreira M, Mesquita M, Quaresma M, Andre S: Prolactin receptor expression in gynaecomastia and male breast carcinoma. Histopathology. 2008, 53: 56-61. 10.1111/j.1365-2559.2008.03059.x.CrossRefPubMed Ferreira M, Mesquita M, Quaresma M, Andre S: Prolactin receptor expression in gynaecomastia and male breast carcinoma. Histopathology. 2008, 53: 56-61. 10.1111/j.1365-2559.2008.03059.x.CrossRefPubMed
57.
go back to reference Forloni F, Giovilli M, Pecis C, Bortolani E, Preziosi A, Barzaghi ME, Corti D, Beck- Peccoz P: Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male. J Endocrinol Invest. 2001, 24: 454-459.CrossRefPubMed Forloni F, Giovilli M, Pecis C, Bortolani E, Preziosi A, Barzaghi ME, Corti D, Beck- Peccoz P: Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male. J Endocrinol Invest. 2001, 24: 454-459.CrossRefPubMed
58.
go back to reference Wennbo H, Tornell J: The role of prolactin and growth hormone in breast cancer. Oncogene. 2000, 19: 1072-1076. 10.1038/sj.onc.1203349.CrossRefPubMed Wennbo H, Tornell J: The role of prolactin and growth hormone in breast cancer. Oncogene. 2000, 19: 1072-1076. 10.1038/sj.onc.1203349.CrossRefPubMed
59.
go back to reference Clevenger CV, Gadd SL, Zheng J: New mechanisms for PRLr action in breast cancer. Trends Endocrinol Metab. 2009, 20: 223-229. 10.1016/j.tem.2009.03.001.CrossRefPubMed Clevenger CV, Gadd SL, Zheng J: New mechanisms for PRLr action in breast cancer. Trends Endocrinol Metab. 2009, 20: 223-229. 10.1016/j.tem.2009.03.001.CrossRefPubMed
60.
go back to reference Speirs V, Shabban AM, Pollock S, Hanby AM, Ball GR, The Male Breast Cancer Consortium: Male versus female breast cancer: study of 523 matched cases reveals differences behind similarity [abstract]. J Pathol. 2010, 222: s8- Speirs V, Shabban AM, Pollock S, Hanby AM, Ball GR, The Male Breast Cancer Consortium: Male versus female breast cancer: study of 523 matched cases reveals differences behind similarity [abstract]. J Pathol. 2010, 222: s8-
61.
go back to reference Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A: Androgen receptor expression is a significant prognostic factor in oestrogen receptor positive breast cancers. Breast Cancer Res Treat. 2010, 124: 607-617. 10.1007/s10549-010-0761-y.CrossRefPubMed Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A: Androgen receptor expression is a significant prognostic factor in oestrogen receptor positive breast cancers. Breast Cancer Res Treat. 2010, 124: 607-617. 10.1007/s10549-010-0761-y.CrossRefPubMed
62.
go back to reference Iredale R, Brain K, Williams B, France E, Gray J: The experiences of men with breast cancer in the United Kingdom. Eur J Cancer. 2006, 42: 334-341. 10.1016/j.ejca.2005.09.027.CrossRefPubMed Iredale R, Brain K, Williams B, France E, Gray J: The experiences of men with breast cancer in the United Kingdom. Eur J Cancer. 2006, 42: 334-341. 10.1016/j.ejca.2005.09.027.CrossRefPubMed
64.
go back to reference Callari M, Cappelletti V, De Cecco L, Musella V, Miodini P, Veneroni S, Gariboldi M, Pierotti MA, Daidone MG: Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat. 2011, 127: 601-10. 10.1007/s10549-010-1015-8.CrossRefPubMed Callari M, Cappelletti V, De Cecco L, Musella V, Miodini P, Veneroni S, Gariboldi M, Pierotti MA, Daidone MG: Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat. 2011, 127: 601-10. 10.1007/s10549-010-1015-8.CrossRefPubMed
65.
go back to reference Johansson I, Nilsson C, Berglund P, Strand C, Jönsson G, Staaf J, Ringnér M, Nevanlinna H, Barkardottir RB, Borg A, Olsson H, Luts L, Fjällskog ML, Hedenfalk I: High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat. 2011, 129: 747-60. 10.1007/s10549-010-1262-8.CrossRefPubMed Johansson I, Nilsson C, Berglund P, Strand C, Jönsson G, Staaf J, Ringnér M, Nevanlinna H, Barkardottir RB, Borg A, Olsson H, Luts L, Fjällskog ML, Hedenfalk I: High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat. 2011, 129: 747-60. 10.1007/s10549-010-1262-8.CrossRefPubMed
67.
go back to reference Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F: Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010, 28: 2114-2122. 10.1200/JCO.2009.25.5729.CrossRefPubMedPubMedCentral Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F: Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010, 28: 2114-2122. 10.1200/JCO.2009.25.5729.CrossRefPubMedPubMedCentral
Metadata
Title
Male breast carcinoma: increased awareness needed
Authors
Jonathan White
Olive Kearins
David Dodwell
Kieran Horgan
Andrew M Hanby
Valerie Speirs
Publication date
01-10-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2930

Other articles of this Issue 5/2011

Breast Cancer Research 5/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine